nmpЖурнал им. Н.В. Склифосовского «Неотложная медицинская помощь»Russian Sklifosovsky Journal "Emergency Medical Care"2223-90222541-8017“N.V. Sklifosovsky Research Institute for Emergency Medicine”nmp-114Research ArticleОБЗОРЫ ЛИТЕРАТУРЫREVIEWS OF LITERATUREПСЕВДОМЕМБРАНОЗНЫЙ КОЛИТ: ДИАГНОСТИКА, ЛЕЧЕНИЕ И ПРОФИЛАКТИКА (ОБЗОР ЛИТЕРАТУРЫ)PSEUDOMEMBRANOUS COLITIS: DIAGNOSIS, TREATMENT AND PREVENTIONЧерненькаяТ. В.ChyornenkayaT. V.

к.м.н., заведующая научной лабораторией

chernenkayat@rambler.ruНИИ скорой помощи им. Н.В. Склифосовского ДЗ г. Москвы, Москва, Российская ФедерацияРоссияN.V. Sklifosovsky Research Institute for Emergency Medicine of the Moscow Healthcare Department, Moscow, Russian FederationRussian Federation201627032016013339Copyright © Черненькая Т.В., 20162016Черненькая Т.В.Chyornenkaya T.V.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jnmp.ru/jour/article/view/114

В последние годы Clostridium difficile стала одним из распространенных и агрессивных внутрибольничных возбудителей. Токсигенный штамм C. difficile является этиологическим агентом псевдомембранозного колита. При отсутствии своевременной адекватной терапии данное заболевание приводит к развитию жизнеугрожающих осложнений. Для предупреждения развития C. difficile-инфекции необходимы оптимизация политики применения антибиотиков в стационаре и строгое соблюдение принципов инфекционного контроля. В настоящем обзоре литературы представлены современные подходы к диагностике, лечению и профилактике инфекции, вызванной C. difficile.

In recent years, Clostridium difficile has become one of the most common and aggressive nosocomial pathogens. The toxigenic strain of C. difficile is the etiological agent of pseudomembranous colitis. This disease leads to the development of dangerous complications without proper therapy. To prevent the C. difficile infection, optimization of in-hospital antibiotics usage and strict compliance with principles of infection control are required. The review of literature presents modern approaches to diagnosis, treatment and prevention of infections, caused by C. difficile.

псевдомембранозный колитClostridium difficileантибиотик-ассоциированная диареяpseudomembranous colitisClostridium difficileantibiotic-associated diarrhea.ReferencesFour-fold difference in antibiotic consumption across the European Region — new WHO report. [Электронный ресурс]. – Режим доступа: http://www.euro.who.int/ru/health-topics/disease-prevention/antimicrobial-resistance/news/news/2014/03/new-data-on-antibiotic-use-ineuropean-regionFour-fold difference in antibiotic consumption across the European Region — new WHO report. Available at: http://www.euro.who.int/ru/health-topics/disease-prevention/antimicrobial-resistance/news/news/2014/03/new-data-on-antibiotic-use-in-european-region (Accessed March 1, 2016)Анализ рынка антибиотиков в России в 2007–2011 гг., прогноз на 2012–2016 гг. [Электронный ресурс]. – Режим доступа: http://marketing.rbc.ru/research/562949983900801.shtmlAnaliz rynka antibiotikov v Rossii v 2007–2011 gg, prognoz na 2012–2016 gg. [Market analysis of antibiotics in Russia in 2007–2011, the forecast for 2012–2016]. Available at: http://marketing.rbc.ru/research/562949983900801.shtml (Accessed March 1, 2016) (In Russian).Ashiru-Oredope D., Sharland M., Charani E., et al. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart – Then Focus // J Antimicrob Chemother. – 2012. – Vol. 67, Suppl. 1. – P. i51–63.Ashiru-Oredope D., Sharland M., Charani E., et al. Improving the quality of antibiotic prescribing in the NHS by developing a new Antimicrobial Stewardship Programme: Start Smart – Then Focus. J Antimicrob Chemother. 2012; 67 Suppl 1: i51–63.Coutsoftides T., Benjamin S. P., Fazio V. W. Pseudomembranous enterocolitis in adults // Ann Surg. – 1979. – Vol. 189, N. 4. – P. 493–495.Coutsoftides T., Benjamin S. P., Fazio V W. Pseudomembranous enterocolitis in adults. Ann Surg. 1979; 189 (4): 493–495.Hummel R.P., Altemeier W.A., Hill E.O. Iatrogenic staphylococcal enterocolitis // Ann Surg. – 1964. – Vol. 160. – P. 551–560.Hummel R.P., Altemeier W.A., Hill E.O. Iatrogenic staphylococcal enterocolitis. Ann Surg. 1964; 160: 551–560.Keeffe E.B., Katon R.M., Chan T.T., et al. Pseudomembranous enterocolitis. Resurgence related to newer antibiotic therapy // West J Med. – 1974. – Vol. 121, N. 6. – P. 462–472.Keeffe E.B., Katon R.M., Chan T.T., et al. Pseudomembranous enterocolitis. Resurgence related to newer antibiotic therapy. West J Med. 1974; 121 (6): 462–472.Chang T.W., Bartlett J.G., Gorbach S.L., Onderdonk A.B. Clindamycininduced enterocolitis in hamsters as a model of pseudomembranous colitis in patients // Infect Immun. – 1978. – Vol. 20, N. 2. – P. 526–529.Chang T.W., Bartlett J.G., Gorbach S.L., Onderdonk A.B. Clindamycininduced enterocolitis in hamsters as a model of pseudomembranous colitis in patients. Infect Immun. 1978; 20 (2): 526–529.George R.H., Symonds J.M., Dimock F., et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis // BMJ. – 1978. – Vol. 1. – P. 695.George R.H., Symonds J.M., Dimock F., et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ. 1978; 1: 695.Bergey’s manual of systematic bacteriology. – Williams&Wilkins, 1986. – Vol. 2. – P. 1165–1167.Bergey’s manual of systematic bacteriology. Williams&Wilkins, 1986. Vol. 2. 1165–1167.Aronsson B., Möllby R., Nord C.E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982 // J Infect Dis. – 1985. – Vol. 151, N. 3. – P. 476–481.Aronsson B., Möllby R., Nord C.E. Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980–1982. J Infect Dis. 1985; 151 (3): 476–481.Alfa M.J., Du T., Beda G. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches // J Clin Microbiol. – 1998. – Vol. 36, N. 7. – P. 2076–2080.Alfa M.J., Du T., Beda G. Survey of incidence of Clostridium difficile infection in Canadian hospitals and diagnostic approaches. J Clin Microbiol. 1998; 36 (7): 2076–2080.Steele J., Chen K., Sun X., et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models // J Infect Dis. – 2012. – Vol. 205. – P. 384–391.Steele J., Chen K., Sun X., et al. Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis. 2012; 205: 384–391.Gonçalves C., Decré D., Barbut F., et al. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile // J Clin Microbiol. – 2004. – Vol. 42, N. 5. – P. 1933–1939.Gonçalves C., Decré D., Barbut F., et al. Prevalence and characterization of a binary toxin (actin-specific ADP-ribosyltransferase) from Clostridium difficile. J Clin Microbiol. 2004; 42 (5): 1933–1939.Schwan C., Stecher B., Tzivelekidis T., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria // PLoS Pathog. – 2009. – Vol. 5, N. 10. – P. e1000626.Schwan C., Stecher B., Tzivelekidis T., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 2009; 5 (10): e1000626.Lanis J.M., Barua S., Ballard J.D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile // PLoS Pathog. – 2010. – Vol. 6, N. 8. – P. e1001061.Lanis J.M., Barua S., Ballard J.D. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 2010; 6 (8): e1001061.Hensgens M.P., Goorhuis A., Dekkers O.M., Kuijper E.J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics // J Antimicrob Chemother. – 2012. – Vol. 67, N. 3. – P. 742–748.Hensgens M.P., Goorhuis A., Dekkers O.M., Kuijper E.J. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother. 2012; 67 (3): 742–748.Garey K.W., Dao-Tran T.K., Jiang Z.D., et al. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broad-spectrum antibiotics // J Hosp Infect. – 2008. – Vol. 70, N. 2. – P. 142–147.Garey K.W., Dao-Tran T.K., Jiang Z.D., et al. A clinical risk index for Clostridium difficile infection in hospitalised patients receiving broadspectrum antibiotics. J Hosp Infect. 2008; 70 (2): 142–147.Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium diffi cile infection // J Hosp Infect. – 2008. – Vol. 70, N. 4. – P. 298–304.Garey K.W., Sethi S., Yadav Y., et al. Meta-analysis to assess risk factors for recurrent Clostridium diffi cile infection. J Hosp Infect. 2008; 70 (4): 298–304.Lucado J., Gould C., Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. [Электронный ресурс]. – Режим доступа http: // www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdfLucado J., Gould C., Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009. Available at: http: //www.hcup-us.ahrq.gov/reports/statbriefs/sb124.pdf (Accessed March 1, 2016)Burckhardt F., Friedrich A., Beier D., Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany // Emerg Infect Dis. – 2008. – Vol. 14, N. 4. – P. 691–692.Burckhardt F., Friedrich A., Beier D., Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany. Emerg Infect Dis. 2008; 14 (4): 691–692.Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections // N Engl J Med. – 2014. – Vol. 370, N. 13. – P. 1198–1208.Magill S.S., Edwards J.R., Bamberg W., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med. 2014; 370 (13): 1198–1208.Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) // Infect Control Hosp Epidemiol. – 2010. – Vol. 31, N. 5. – P. 431–455.Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31 (5): 431–455.Bobo L.D., Dubberke E.R., Kollef M. Clostridium difficile in the ICU // Chest. – 2011. – Vol. 140, N. 6. – P. 1643–1653.Bobo L. D., Dubberke E. R., Kollef M. Clostridium difficile in the ICU. Chest. 2011; 140 (6): 1643–1653.Wenisch J.M., Schmid D., Kuo H.W., et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease // Eur J Clin Microbiol Infect Dis. – 2012. – Vol. 31, N. 8. – P. 1923–1930.Wenisch J.M., Schmid D., Kuo H.W., et al. Hospital-acquired Clostridium difficile infection: determinants for severe disease. Eur J Clin Microbiol Infect Dis. 2012; 31 (8): 1923–1930.Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey // Lancet. – 2011. – Vol. 377. – P. 63–73.Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet. 2011; 377: 63–73.Berdichevski T., Keller N., Rahav G., et al. The impact of pseudo - membrane formation on the outcome of Clostridium difficile associated disease // Infection. – 2013. – Vol. 41, N. 5. – P. 969–977.Berdichevski T., Keller N., Rahav G., et al. The impact of pseudo - membrane formation on the outcome of Clostridium difficile associated disease. Infection. 2013; 41 (5): 969–977.Lessa F.C., Mu Y., Bamberg W.M., et al. Burden of Clostridium difficile Infection in the United States // N Engl J Med. – 2015. – Vol. 372. – P. 825–834.Lessa F.C., Mu Y., Bamberg W.M., et al. Burden of Clostridium difficile Infection in the United States. N Engl J Med. 2015; 372: 825–834.Lamontagne F., Labbe A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain // Ann Surg. – 2007. – Vol. 245, N. 2. – P. 267–272.Lamontagne F., Labbe A.C., Haeck O., et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg. 2007; 245 (2): 267–272.Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection // Clin Infect Dis. – 2008. – Vol. 46, Suppl. 1. – P. S12–18.Bartlett J.G., Gerding D.N. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis. 2008; 46 Suppl 1: S 12–18.Crobach M.J., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI) // Clin Microbiol Infect. – 2009. – Vol. 15, N. 12. – P. 1053–1066.Crobach M.J., Dekkers O.M., Wilcox M.H., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect. 2009; 15 (12): 1053–1066.Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections // Am J Gastroenterol. – 2013. – Vol. 108, N. 4. – P. 478–498.Surawicz C.M., Brandt L.J., Binion D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013; 108 (4): 478–498.Debast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. [Электронный ресурс]. – Режим доступа: http://onlinelibrary.wiley.com/doi/10.1111/1469-0691.12418/fullDebast S.B., Bauer M.P., Kuijper E.J. European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Available at: http://onlinelibrary.wiley. com/doi/10.1111/1469-0691.12418/full (Accessed March 1, 2016)A practical guidance document for the laboratory detection of toxigenic Clostridium difficile.- Washington, DC: American Society for Microbiology, Sept. 21, 2010. [Электронный ресурс]. – Режим доступа: http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf.A practical guidance document for the laboratory detection of toxigenic Clostridium difficile. Washington, DC: American Society for Microbiology, Sept. 21, 2010. Available at: http://www.asm.org/images/pdf/Clinical/clostridiumdifficile9-21.pdf. (Accessed March 1, 2016)Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity // Clin Infect Dis. – 2007. – Vol. 45, N. 3. – P. 302–307.Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007. 45 (3): 302–307.Kopterides P., Papageorgiou C., Antoniadou A., et al. Failure of tigecycline to treat severe Clostridium difficile infection // Anaesth Intensive Care. – 2010. – Vol. 38, N. 4. – P. 755–758.Kopterides P., Papageorgiou C., Antoniadou A., et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care. 2010; 38 (4): 755–758.Kleger A., Schnell J., Essig A., et al. Fecal transplant in refractory Clostridium difficile colitis // Dtsch Arztebl Int. – 2013. – Vol. 110, N. 7. – P. 108–115.Kleger A., Schnell J., Essig A., et al. Fecal transplant in refractory Clostridium difficile colitis. Dtsch Arztebl Int. 2013; 110 (7): 108–115.Petrof E.O., Khoruts A. From stool transplants to next-generation microbiota therapeutics // Gastroenterology. – 2014. – Vol. 146, N. 6. – P. 1573–1582.Petrof E.O., Khoruts A. From stool transplants to next-generation microbiota therapeutics. Gastroenterology. 2014; 146 (6): 1573–1582.Freeman J., Baines S.D., Todhunter S.L., et al. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole // J Antimicrob Chemother. – 2011. – Vol. 66, N. 6. – P. 1407– 1408.Freeman J., Baines S.D., Todhunter S.L., et al. Nitazoxanide is active against Clostridium difficile strains with reduced susceptibility to metronidazole. J Antimicrob Chemother. 2011; 66 (6): 1407–1408.Carman R.J., Boone J.H., Grover H., et al. In vivo selection of rifamycinresistant Clostridium difficile during rifaximin therapy // Antimicrob Agents Chemother. – 2012. – Vol. 56, N. 11. – P. 6019–6020.Carman R.J., Boone J.H., Grover H., et al. In vivo selection of rifamycin- resistant Clostridium difficile during rifaximin therapy. Antimicrob Agents Chemother. 2012; 56 (11): 6019–6020.Mattila E., Arkkila P., Mattila P.S., et al. Rifaximin in the treatment of recurrent Clostridium difficile infection // Aliment Pharmacol Ther. – 2013. – Vol. 37, N. 1. – P. 122–128.Mattila E., Arkkila P., Mattila P.S., et al. Rifaximin in the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther. 2013; 37 (1): 122–128.Allen S.J., Wareham K., Wang D., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older patients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial // Lancet. – 2013. – Vol. 382. – P. 1249–1257.Allen S.J., Wareham K., Wang D., et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficilediarrhoea in older inpatients (PLACIDE): a randomised, doubleblind, placebo-controlled, multicentre trial. Lancet. 2013; 382: 1249– 1257.Rainkie D., Kolber M.R. Probiotics for the prevention of Clostridium difficile // Can Fam Physician. – 2013. – Vol. 59, N. 9. – P. 957.Rainkie D., Kolber M.R. Probiotics for the prevention of Clostridium difficile. Can Fam Physician. 2013; 59 (9): 957.Issa I., Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? // World J Gastroenterol. – 2014. – Vol. 20, N. 47. – P. 17788–17795.Issa I., Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? World J Gastroenterol. 2014; 20 (47): 17788–17795.Flatley E.A., Wilde A.M., Nailor M.D. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection // J Gastrointestin Liver Dis. – 2015. – Vol. 24, N. 1. – P. 21–24.Flatley E.A., Wilde A.M., Nailor M.D. Saccharomyces boulardii for the prevention of hospital onset Clostridium difficile infection. J Gastrointestin Liver Dis. 2015; 24 (1): 21–24.Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children // Cochrane Database Syst Rev. – 2013. – Vol. 5. –CD006095. doi: 10.1002/14651858.CD006095.Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013; 5: CD006095. doi: 10.1002/14651858. CD006095.Dubberke E.R., Reske K.A., Noble-Wang J., et al. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities // Am J Infect Control. – 2007. – Vol. 35, N. 5. – P. 315–318.Dubberke E.R., Reske K.A., Noble-Wang J., et al. Prevalence of Clostridium difficile environmental contamination and strain variability in multiple health care facilities. Am J Infect Control. 2007; 35 (5): 315–318.Walker N., Gupta R., Cheesbrough J. Blood pressure cuffs: friend or foe? // J Hosp Infect. – 2006. – Vol. 63, N. 2. – P. 167–169.Walker N., Gupta R., Cheesbrough J. Blood pressure cuffs: friend or foe? J Hosp Infect. 2006; 63 (2): 167–169.Wilcox M.H., Shetty N., Fawley W.N., et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England // Clin Infect Dis. – 2012. – Vol. 55, N. 8. – P. 1056–1063.Wilcox M.H., Shetty N., Fawley W.N., et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping-based surveillance scheme in England. Clin Infect Dis. 2012; 55 (8): 1056–1063.Jen M.H., Saxena S., Bottle A., et al. Assessment of administrative data for evaluating the shifting acquisition of Clostridium difficile infection in England // J Hosp Infect. – 2012. – Vol. 80, N. 3. – P. 229–237.Jen M.H., Saxena S., Bottle A., et al. Assessment of administrative data for evaluating the shifting acquisition of Clostridium difficile infection in England. J Hosp Infect. 2012; 80 (3): 229–237.Boyce J.M., Ligi C., Kohan C., et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs // Infect Control Hosp Epidemiol. – 2006. – Vol. 27, N. 5. – P. 479–483.Boyce J.M., Ligi C., Kohan C., et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol. 2006; 27 (5): 479–483.М.Б. Богданов, Т.В. Черненькая. Алгоритмы и организация антибиотикотерапии: руководство для врачей. М.: Видар. 2004. 219 с.M.B. Bogdanov, T.V. Chernen’kaya. Algoritmy i organizatsiya antibiotikoterapii: rukovodstvo dlya vrachey [Algorithms and organization of antibiotic therapy]. Moscow: Vidar Publ., 2004. 219 p. (In Russian).Nuila F., Cadle R.M., Logan N., et al. Antibiotic stewardship and Clostridium difficile-associated disease // Infect Control Hosp Epidemiol. – 2008. – Vol. 29, N. 11. – P. 1096–1097.Nuila F., Cadle R.M., Logan N., et al. Antibiotic stewardship and Clostridium difficile-associated disease. Infect Control Hosp Epidemiol. 2008; 29 (11): 1096–1097.

The authors declare that there are no conflicts of interest present.